AU754399B2 - Novel indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer - Google Patents

Novel indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer Download PDF

Info

Publication number
AU754399B2
AU754399B2 AU47766/99A AU4776699A AU754399B2 AU 754399 B2 AU754399 B2 AU 754399B2 AU 47766/99 A AU47766/99 A AU 47766/99A AU 4776699 A AU4776699 A AU 4776699A AU 754399 B2 AU754399 B2 AU 754399B2
Authority
AU
Australia
Prior art keywords
composition
matter
tau
carbons
halide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU47766/99A
Other languages
English (en)
Other versions
AU4776699A (en
Inventor
David R. Brittelli
Timothy B. Lowinger
Hanno Roder
Michael C. Van Zandt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nad AG
Original Assignee
NAP AG
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NAP AG, Bayer AG filed Critical NAP AG
Publication of AU4776699A publication Critical patent/AU4776699A/en
Application granted granted Critical
Publication of AU754399B2 publication Critical patent/AU754399B2/en
Assigned to NAD AKTIENGESELLSCHAFT reassignment NAD AKTIENGESELLSCHAFT Request to Amend Deed and Register Assignors: NAP AG
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU47766/99A 1998-07-02 1999-06-23 Novel indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer Ceased AU754399B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/109131 1998-07-02
US09/109,131 US6013646A (en) 1998-07-02 1998-07-02 Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
PCT/EP1999/004369 WO2000001699A1 (en) 1998-07-02 1999-06-23 Novel indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer

Publications (2)

Publication Number Publication Date
AU4776699A AU4776699A (en) 2000-01-24
AU754399B2 true AU754399B2 (en) 2002-11-14

Family

ID=22325955

Family Applications (1)

Application Number Title Priority Date Filing Date
AU47766/99A Ceased AU754399B2 (en) 1998-07-02 1999-06-23 Novel indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer

Country Status (6)

Country Link
US (2) US6013646A (enExample)
EP (1) EP1091962A1 (enExample)
JP (1) JP2002519425A (enExample)
AU (1) AU754399B2 (enExample)
CA (1) CA2336419A1 (enExample)
WO (1) WO2000001699A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013646A (en) 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US6660750B2 (en) 2000-02-15 2003-12-09 University Of Iowa Research Foundation Flavopiridol methods and compositions for HIV therapy
US20030181473A1 (en) * 2000-02-29 2003-09-25 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with taxane compounds
AU2001261324A1 (en) * 2000-05-08 2001-11-20 Psoriasis Research Institute Psoriasis treatment
US7129250B2 (en) * 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
CA2308994A1 (en) * 2000-05-19 2001-11-19 Aegera Therapeutics Inc. Neuroprotective compounds
DE60229437D1 (de) * 2001-12-13 2008-11-27 Pharmacyclics Inc Verfahren zur beeinflussung neurologischer progression
DE10161940A1 (de) * 2001-12-17 2003-07-03 Nad Ag N-Carbacyclus-monosubstitutierte Indolocarbazole als Proteinkinase-inhibitoren
WO2003078448A1 (en) * 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
DE10255343B4 (de) * 2002-11-27 2006-09-07 Nad Ag N,N-Verbrückte, Stickstoff-Substituierte Carbacyclische Indolocarbazole als Proteinkinase-Inhibitoren
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
CN1984663A (zh) 2004-03-29 2007-06-20 南佛罗里达大学 用曲西瑞宾和相关化合物有效治疗肿瘤和癌症
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
DE102004025726B4 (de) 2004-05-26 2006-07-06 Roder, Hanno, Dr. Verwendung eines spezifischen K252a-Derivats zur Verhinderung oder Behandlung der Alzheimerschen Krankheit
US20060058250A1 (en) * 2004-09-10 2006-03-16 Cephalon, Inc. Methods of treating proliferative skin diseases using carbazole derivatives
WO2006084033A1 (en) * 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
EP1876900A4 (en) * 2005-05-02 2009-06-24 Univ Columbia PHOSPHOINOSITIDE MODULATION FOR THE TREATMENT OF ALZHEIMER DISEASE
US20070249590A1 (en) * 2005-10-28 2007-10-25 Wilson Lawrence J Substituted indolo[2,3-a]pyrrolo[3,4-c]carbazole compounds useful in treating kinase disorders
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
EP2124554B1 (en) * 2006-12-14 2012-02-08 Tautatis, Inc. Compositions and methods for the treatment of cancer
US20100273769A1 (en) * 2009-01-26 2010-10-28 Hanno Roder Composition and method for the treatment of parkinson's disease

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968690A (en) * 1986-05-27 1990-11-06 United States Government As Represented By The Secretary Of The Dept. Of Health And Human Services 3-deazaneplanocin, intermediates for it, and antiviral composition and method of treatment using it
WO1988007045A1 (fr) * 1987-03-09 1988-09-22 Kyowa Hakko Kogyo Co., Ltd. Derives de la substance physiologiquement active k-252
JPH07113027B2 (ja) * 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
US5618809A (en) * 1989-12-14 1997-04-08 Schering Corporation Indolocarbazoles from saccharothrix aerocolonigenes copiosa subsp. nov SCC 1951 ATCC 53856
US5189046A (en) * 1990-08-14 1993-02-23 Nova Pharmaceutical Corporation Protein kinase C modulators
JPH04187686A (ja) * 1990-11-20 1992-07-06 Meiji Seika Kaisha Ltd インドロカルバゾール誘導体
US5955444A (en) 1991-08-09 1999-09-21 Massachusetts Institute Of Technology Method of inhibiting abnormal tau hyper phosphorylation in a cell
DE69232121T2 (de) * 1991-08-09 2002-06-20 Massachusetts Institute Of Technology, Cambridge Verwendungen einer proteinkinase von ton und neurofilament pk40
NZ245203A (en) * 1991-11-29 1997-07-27 Banyu Pharma Co Ltd 5h-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6h)-dione derivatives substituted in position-13 by a pentose or hexose group; corresponding indolo-furano(anhydride)intermediates
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
EP0575955B1 (en) * 1992-06-22 1999-09-15 Kyowa Hakko Kogyo Co., Ltd. Process for producing staurosporine derivatives
US5621101A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
JPH08500112A (ja) * 1992-08-12 1996-01-09 ジ・アップジョン・カンパニー タキソールと組み合わせるプロテインキナーゼ阻害剤および関連化合物
WO1994020106A1 (fr) * 1993-03-03 1994-09-15 Kyowa Hakko Kogyo Co., Ltd. Renforceur de sensibilite pour agent antineoplasique
WO1994027982A1 (en) * 1993-05-28 1994-12-08 Cephalon, Inc. Use of indolocarbazole derivatives to treat a pathological condition of the prostate
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
EP1449529B1 (en) * 1993-12-23 2010-01-27 Eli Lilly And Company Protein Kinase C Inhibitors
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
WO1995022331A1 (en) * 1994-02-18 1995-08-24 Cephalon, Inc. Aqueous indolocarbazole solutions
US5491242A (en) * 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
US5594009A (en) * 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5648378A (en) * 1995-06-07 1997-07-15 Research Corporation Technologies, Inc. 2-iminochromene derivatives as inhibitors of protein tyrosine kinase
US6013646A (en) 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer

Also Published As

Publication number Publication date
JP2002519425A (ja) 2002-07-02
EP1091962A1 (en) 2001-04-18
WO2000001699A1 (en) 2000-01-13
AU4776699A (en) 2000-01-24
US6541468B1 (en) 2003-04-01
CA2336419A1 (en) 2000-01-13
US6013646A (en) 2000-01-11

Similar Documents

Publication Publication Date Title
US6013646A (en) Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
EP2306836B1 (en) Bmi-1 protein expression modulators
KR102534962B1 (ko) 8,9-디하이드로이미다졸[1,2-a]피리미도[5,4-e]피리미딘-5(6H)-케톤계 화합물
AU2009270856B2 (en) Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
JP6430483B2 (ja) 化学療法の間の正常細胞の一時的な保護
US20040102467A1 (en) Neuroprotective and anti-proliferative compounds
CN114502559B (zh) 二氢咪唑并嘧啶并嘧啶酮类化合物
KR20240172217A (ko) 암 치료를 위한 락테이트/atp 생성 억제제로서의 n-(3-(벤조[b]티오펜-2-카르복스아미도)-페닐)-2,3-디하이드로벤조[b][1,4]다이옥신-6-카르복스아미드 유도체 및 관련 화합물
CN112689528B (zh) 嘧啶基-杂芳氧基-萘基化合物和使用方法
WO2016010926A1 (en) Btk inhibitors for the treatment of cns malignancies
US7129250B2 (en) Neuroprotective and anti-proliferative compounds
CN115697331A (zh) Taspase1抑制剂及其用途
US11787794B2 (en) Aminothiazole compounds and methods using same
KR20240128040A (ko) 2 고리성 골격을 갖는 1h-피라졸-3-아민 유도체
WO2014089571A1 (en) Anticancer compounds
WO2025171226A1 (en) Compositions and methods for inducing ferroptosis
WO2025171225A1 (en) Compositions and methods for inducing ferroptosis
CA2409355A1 (en) Neuroprotective and anti-proliferative compounds

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: BAYER AKTIENGESELLSCHAFT, NAD AKTIENGESELLSCHAFT

Free format text: FORMER NAME WAS: BAYER AKTIENGESELLSCHAFT, NAP AG

HB Alteration of name in register

Owner name: NAD AKTIENGESELLSCHAFT

Free format text: FORMER NAME WAS: NAP AG

TH Corrigenda

Free format text: IN VOL 17, NO 13, PAGE(S) 420 UNDER THE HEADING ALTERATION OF NAME IN REGISTER THE NAME OF THE APPLICANT IN REGARD TO PATENT NUMBER 754399 SHOULD HAV DELETED: BAYER AKTIENGESELLSCHAFT

SREP Specification republished
TH Corrigenda

Free format text: IN VOL 16, NO 40, PAGE(S) 7738 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX IN THE NAME OF BAYER AKTIENGESELLSCHAFT, NAP AG, SERIAL NO. 754399, INID (71), DELETE THE FIRST APPLICANT NAMELY BAYER AKTIENGESELLSCHAFT